EUROPEAN COMMITTEE FOR COSMETICS AND CONSUMER HEALTH (CD-P-COS)

Set up by the Committee of Ministers under Article 17 of the Statute of the Council of Europe and in accordance with Resolution CM/Res(2011)24 on intergovernmental committees and subordinate bodies, their terms of reference and working methods.

Type of committee: Steering Committee

Terms of reference valid from: 1 January 2020 until 31 December 2021

<table>
<thead>
<tr>
<th>PILLAR/PROGRAMME/SUB-PROGRAMME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pillar: Rule of Law</td>
</tr>
<tr>
<td>Programme: Action against crime, safety and security of citizens</td>
</tr>
<tr>
<td>Sub-Programme: Quality of Medicines and Healthcare (EDQM, Pharmacopoeia)</td>
</tr>
</tbody>
</table>

MAIN TASKS

Under the authority of the Committee of Ministers and in its composition restricted to the representatives of the States Parties to the Convention on the Elaboration of a European Pharmacopoeia, the Committee for Cosmetics and Consumer Health (CD-P-COS) is instructed to:

(i) foster co-operation among member States and in particular promote technical collaboration in the field of market surveillance by Official Cosmetics Control Laboratories (OCCLs) and work towards mutual recognition of test results;
(ii) identify emerging health threats related to the use of cosmetic products and consult with the European Network of OCCLs to ensure that they are adequately addressed; identify potential priorities for the work to be performed in the Network of OCCLs (e.g. test methods and market surveillance studies);
(iii) where deemed necessary, prepare proposals for resolutions for adoption by the Committee of Ministers;
(iv) respond to health risks posed by the use of specific ingredients with pharmacological or toxic effects in cosmetics and, where appropriate, propose appropriate measures and set standards and define policies;
(v) considering that the scope also includes products applied intra-dermally for aesthetic and/or decorative purposes and other related borderline products not necessarily falling under the definition of a cosmetic product as given in Regulation (EC) No 1223/2009 on cosmetic products, address also questions of quality and safety of tattoos and permanent make-up. Products classified as medicinal products or medical devices are excluded from the terms of reference of this Committee;
(vi) hold an exchange of views annually in order to evaluate its activities and advise the Committee of Ministers and the Secretary General on future priorities in its sector, including possible new activities and those that might be discontinued;
(vii) take due account of a gender perspective in the performance of its tasks;
(viii) take the pertinent aspects of the European Convention on Human Rights into consideration in its thematic work.

SPECIFIC TASKS

(i) Enhance the control of cosmetics and mutual recognition of results as part of a common work programme of CD-P-COS and the network of OCCLs;
(ii) Promote the distribution of the Council of Europe’s knowledge overview publication on safer tattooing and propose further measures when deemed necessary.
(iii) Update existing guidelines (e.g. “Safe cosmetics for young children” or on essential oils) as needed.
(iv) Review progress towards the United Nations Sustainable Development Goals (UNSDGs), as evidenced by monitoring mechanisms and promoted through standard-setting and exchange of experiences and good practices.

COMPOSITION

Members:

Governments of the States Parties to the Convention on the Elaboration of a European Pharmacopoeia are invited to designate a representative of the highest possible rank with expertise for the implementation of national policies and surveillance programmes relating to cosmetic products. Each member of the Committee shall have one vote. Where a government designates more than one member, only one of them is entitled to take part in the voting.

The sending authorities of these States will bear the travel and subsistence expenses for their representatives’ participation in the meetings of the CD-P-COS. The travel and subsistence expenses of the Chair will be borne by the EDQM budget.
**Participants:**
The following may send representatives, without the right to vote and at the charge of their corresponding administrative budgets:
- Parliamentary Assembly of the Council of Europe;
- Congress of Local and Regional Authorities of the Council of Europe;
- European Court of Human Rights;
- Council of Europe Commissioner for Human Rights;
- Conference of INGOs of the Council of Europe;
- Committees or other bodies of the Council of Europe engaged in related work, as appropriate.

The following may send representatives, without the right to vote and without defrayal of expenses:
- Council of Europe member States other than those mentioned above under “Members” and other States with observer status to the European Pharmacopoeia Commission;
- European Union;
- Observer States to the Council of Europe: Canada, Holy See, Japan, Mexico, United States of America;

**Observers:**
The following may send representatives, without the right to vote and without defrayal of expenses:
- non-member States with which the Council of Europe has a Neighbourhood Partnership including relevant co-operation activities.

**Working Methods**

**Plenary meetings:**
38 members, 1 meeting in 2020, 1 day
38 members, 1 meeting in 2021, 1 day

Extraordinary meetings of the CD-P-COS can be convened upon request by the Chairperson.

Representatives taking part in the Committee and its subordinate bodies shall complete a declaration of interest and confidentiality undertaking form (EDQM Form/226).

The Committee will also appoint a Gender Equality Rapporteur from amongst its members.

The rules of procedure of the Committee are governed by Resolution CM/Res(2011)24 on intergovernmental committees and subordinate bodies, their terms of reference and working methods.

With a view to reaching its objectives and to enable multidisciplinary working methods, the CD-P-COS may, in derogation of Resolution CM/Res(2011)24 and within the limits of budgetary appropriations, create subordinate bodies.

Whenever appropriate, it will prioritise environmentally sound working methods, such as virtual meetings facilitated by information technology and written consultations.

**Budgetary Information**

<table>
<thead>
<tr>
<th></th>
<th>Meetings per year</th>
<th>Number of days</th>
<th>Members</th>
<th>Plenary €K</th>
<th>Bureau €K</th>
<th>Working groups</th>
<th>Secretariat (A, B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>1</td>
<td>1</td>
<td>38</td>
<td>2.2</td>
<td>-</td>
<td>-</td>
<td>1 A; 1 B</td>
</tr>
<tr>
<td>2021</td>
<td>1</td>
<td>1</td>
<td>38</td>
<td>2.2</td>
<td>-</td>
<td>-</td>
<td>1 A; 1 B</td>
</tr>
</tbody>
</table>

*The costs include the per diem, travel costs, interpretation, translation and document printing. These costs are calculated on the basis of the 2020 standard costs.*